Novavax COVID vaccine has shown great efficacy against coronavirus, Including variablesAccording to the results of a large study.
The injections were 90 percent effective in preventing symptoms of COVID and 100% effective in preventing moderate to severe symptomsThe US biotech company reported on Monday. injection was 93% effective against variables of concernadded.
The vaccine uses recombinant protein technology, which is also used in a candidate vaccine developed by Sanofi and GlaxoSmithKline.
The vaccine’s overall efficacy has exceeded 90 percent, which is close to the reported rates for the injection of messenger RNA developed by Pfizer, BioNTech and Moderna, as well as the Russian Sputnik V vaccine, which uses technology from viral vectors. However, immunologists tend to caution against comparing efficacy results in different trials, Because the conditions and evaluation methods are not the same.
Phase 3 trial of Novavax included Nearly 30,000 participants from the United States and Mexicoand analyzed the vaccine’s efficacy against major variants circulating in the United States, as defined by the Centers for Disease Control and Prevention (CDC, for its English acronym). Only one case of the highly contagious Delta strain was detected, first identified in India and still rare in the United States, Among the participants in the experiment, so the effectiveness of the injection is not conclusive.
In the results of a trial of 15,000 people in the UK published in March, the injection was found to be 90% effective in preventing COVID symptoms in all variants and the original version of the virus.
The company said earlier that it would not apply for a license for the vaccine in the United States and Europe until the third quarter of this year. Novavax has confirmed that it is on track to reach a manufacturing capacity of 100 million doses per month By the end of the third chapter and 150 million per month by the end of 2021.
“Novavax is one step closer to addressing the critical and ongoing global public health need for additional COVID-19 vaccines,” CEO Stanley C. Erk said in a statement.
“Novavax continues to work with a sense of urgency to complete our regulatory filings and bring this vaccine, built on a known and proven platform, to a world still in dire need of vaccines.”